Cellular immunotherapy plus chemotherapy ameliorates survival in gastric cancer patients: a meta-analysis
- PDF / 1,797,780 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 109 Downloads / 204 Views
REVIEW ARTICLE
Cellular immunotherapy plus chemotherapy ameliorates survival in gastric cancer patients: a meta‑analysis Guoming Hu1 · Kefang Zhong1 · Songxiang Wang1 · Shimin Wang2 · Qiannan Ding3 · Feng Xu1 · Wei Chen1 · Pu Cheng4 · Liming Huang1 Received: 16 March 2020 / Accepted: 3 July 2020 © Japan Society of Clinical Oncology 2020
Abstract The efficacy of cellular immunotherapy plus chemotherapy in treatment of gastric cancer (GC) remains inconsistent even controversial. Hence, we performed a meta-analysis to better comprehend the clinical value of cellular immunotherapy plus chemotherapy for GC patients. We searched PubMed, Embase and EBSCO databases to identify the studies evaluating the association of cellular immunotherapy plus chemotherapy and overall survival (OS) and/or disease-free survival (DFS) in patients with GC, and then combined relevant data into hazard ratios (HRs) for OS, DFS and clinicopathological features such as TNM stage, etc. with STATA 12.0. Eleven studies with 1244 patients were included in this meta-analysis. We found that cellular immunotherapy plus chemotherapy remarkably improved overall survival (OS) and diseases-free survival (DFS) as compared to the chemotherapy for GC patients. In subgroup analyses, pooled data showed that the combined therapy was significantly associated with better 3-year and 5-year survival rate, but not with 1-year survival rate of patients; the application of cellular immunotherapy based on either CIK or DC-CIK cells could enhance survival as well as NK, γδT and CIK cells-based immunotherapy. More importantly, the addition of cellular immunotherapy considerably improved OS and DFS only in patients with stage III rather than stage II. In addition, we also discovered that the combined therapy did not cause intolerable side effects to patients. Cellular immunotherapy plus chemotherapy ameliorates survival in GC, especially in patients with stage III, implicating that it is a valuable therapeutic strategy for these patients. Keywords Cellular immunotherapy plus chemotherapy · Favorable outcome · Gastric cancer · Meta-analysis
Introduction
Guoming Hu and Kefang Zhong shared as co-first authors. Electronic supplementary material The online version of this article (https://doi.org/10.1007/s10147-020-01750-6) contains supplementary material, which is available to authorized users. * Guoming Hu [email protected] * Pu Cheng [email protected] * Liming Huang [email protected] 1
Department of General Surgery (Breast and Thyroid Surgery), Shaoxing People’s Hospital, Shaoxing Hospital, Zhejiang University School of Medicine, 568 Zhongxing Road, Shaoxing 312000, Zhejiang, China
Human gastric cancer (GC) is one of the most common fatal malignancies worldwide. Surgical treatment is considered to be an effective strategy for GC. Although the application of postoperative adjuvant chemotherapy and targeted therapy including Herceptin can to some extent reduce the recurrence and improve patients’ survival, the prognosis 2
Department of Nephrology, Shaoxing
Data Loading...
